Company intelligence / Profile preview
nCage Therapeutics
Krakow, Malopolskie, Polandncage.org ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
nCage Therapeutics has demonstrated in animal models that its programmable synthetic VLP platform can elicit increased B and T cell responses compared to current vaccine technologies. The lead universal flu vaccine candidate is in preclinical development with animal challenge model data expected by the end of 2025. Other pipeline candidates are also at the preclinical stage.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Synthetic viral-like particles (VLPs)Protein cagesImmunostimulants (for vaccines)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Ryvu Therapeutics – collaboration on next-generation ADC platform technology
Beyond the preview
Go deeper on nCage Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nCage Therapeutics.